You paid for the research that gave us the COVID vaccine. You paid for the algorithms that run Google Search. You paid for the battery tech in every electric car on the road. And then, when these things hit the market, you paid again — at a premium.
That’s not innovation. That’s a one-way valve. And it’s the biggest heist you never knew you were part of.
Let’s start with a simple fact: more than 60% of the foundational patents behind modern pharmaceuticals trace back to government-funded labs. The NIH, not Pfizer, figured out the mRNA platform. The Department of Energy, not Tesla, solved the lithium-ion chemistry. The NSF, not Google, laid the groundwork for hypertext and search algorithms.
Every time you buy a drug, a software license, or a smartphone, you’re paying twice: once as a taxpayer, once as a customer.
We call this the ‘innovation pipeline.’ It’s supposed to be a virtuous cycle: public risk, private engineering, shared reward. But the reward isn’t shared. It’s hoarded. Corporations take the public’s high-risk, long-horizon science — the stuff that would never get a venture capitalist to write a check — and wrap it in patents, licenses, and proprietary walls. Then they sell it back to the same taxpayers who funded the original work.
You’ve probably noticed the pattern. Universities produce breakthroughs. Spin-offs commercialize them. Big pharma or big tech buys the spin-off, adjusts the price, and calls it ‘innovation.’ The public foots the bill for the basic science, then foots the bill again for the product. And the company pockets the difference.
This isn’t a bug. It’s the system.
Take the case of remdesivir. Gilead charged $3,120 per course. The drug was built on research funded by the U.S. government and other public agencies. When asked about the price, executives pointed to ‘investment in innovation.’ Meanwhile, the taxpayers who paid for that innovation saw zero return — except the privilege of buying the drug at a markup.
When you privatize the upside and socialize the downside, you’re not building a market — you’re running a subsidy.
Now, the standard defense is that private companies add essential value — manufacturing, trials, distribution. And that’s true. But it’s also true that the ratio of public risk to private reward has become grotesque. A 2019 study found that NIH-funded research contributed to every single one of the 210 new drugs approved by the FDA between 2010 and 2016. Yet the government owns none of those patents. The public gets back exactly nothing from the billions it invested.
You want to know why healthcare costs are crippling Americans? Start here. You want to know why college textbooks cost $400? Because the same dynamic plays out in academic publishing. You want to know why your internet bill keeps rising? Because the backbone of the internet was built with public funds, then handed to private providers.
This is the Mimeng Principle in action: the public sows, the private reaps, and everyone calls it progress.
But here’s the twist that most people miss. The same people who champion open science as a way to accelerate discovery are often the same people who defend patents as essential for innovation. They don’t see the contradiction. They celebrate when a government-funded breakthrough becomes a startup — Look, public money works! — and then they cheer when that startup gets acquired or goes public, without asking where the long-term value went.
We’ve built a system where the public takes the risk and the private takes the credit. That’s not a partnership. That’s a con.
How do we fix it? Not by killing patents, but by rebalancing them. The government could negotiate for a share of revenues from any product that emerged from public funding. Universities could license technology with price caps. Or we could simply fund more research that stays in the public domain — no patents, no licensing fees, just freely available science.
But don’t hold your breath. The machinery of appropriation is too comfortable. The people who benefit from this one-way valve write the laws, pay the lobbyists, and fund the think tanks that tell us ‘taxpayer-funded research is the seed, private industry is the farmer.’ They want you to believe the farmer deserves the whole harvest.
You don’t have to accept that story. The next time someone tells you ‘innovation is alive and well,’ ask them who paid for the raw material. Ask them why you’re paying retail for something you already bought wholesale.
Because the truth is simple: you already paid for it. They’re just making you pay again.
FAQ
Q: Isn't it fair for companies to profit from turning basic research into usable products?
A: It's fair to profit from the value they add — manufacturing, trials, distribution. But not to capture all the upside of publicly-funded science while the public bears the risk. The imbalance is the problem, not profit itself.
Q: What's a practical policy change that could fix this?
A: The government could require that any patent derived from federal funding include a clause for reasonable pricing, or a revenue share back to the public. Or simply fund more open-access research that can't be patented.
Q: Doesn't this argument sound like anti-capitalist rhetoric?
A: Not at all. It's pro-market. A genuine market would price risk and reward accurately. Right now, the public's risk is invisible and uncompensated. Calling that out isn't anti-capitalist — it's anti-rent-seeking.